glp-1 and gastric bypass Metabolic Bariatric Surgery vs. Receptor Agonists for Obesity Management Tired of GLP-1s? Comparing Gastric

What you eat, how you move, and what supplements you take all influence outcomes

Nausea affects 15-40% of patients (varying by product and dose) and is often the most troublesome early symptom

Developed initially to manage diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have skyrocketed in popularity since the US Food & Drug Administration first approved semaglutide (brand name Ozempic/Wegovy) for weight loss in 2021

And they come with a warning about the potential for thyroid cancer

10.2337/diabetes.50.11.2497 55

The biological mechanism remains active, but the magnitude and durability of metabolic effects at those lower doses have not been established in clinical trials